Cambridge COVID vaccine is multipurpose DNA vector delivery system based and customised COVID vaccine.
It is developed on a foundation of libraries of computer-generated antigen structures encoded by synthetic genes that can train the human immune system to target key regions of the virus and to produce beneficial anti-viral responses.
This 'laser-specific' computer generated approach is able to help avoid the adverse hyper-inflammatory immune responses that can be triggered by recognition of the wrong parts on the coronavirus's surface.
Professor Jonathan Heeney, head of the Laboratory of Viral Zoonotics at the University of Cambridge, and founder of DIOSynVax, said: "Our approach involves 3D computer modelling of the SARS-CoV-2 virus's structure. It uses information on the virus itself as well as its relatives - SARS, MERS and other coronaviruses carried by animals that threaten to 'spill-over' to humans again to cause future human epidemics."
He further says " Ultimately we aim to make a vaccine that will not only protect from SARS-CoV-2, but also other related coronaviruses that may spill over from animals to humans."
DNA vector based delivery system
DIOSynVax's is based around DNA vector based delivery system.Otherviral vaccines are based on RNA or adenoviruses to deliver their antigens.
These synthetic gene inserts are very versatile and can also be placed within a number of different vaccine delivery systems that other companies are using. Once an antigen is identified, the key piece of genetic code that the virus uses to produce the essential parts of its structure is inserted into a DNA parcel known as a vector. The body's immune cells take up the vector.
This DNA vector has already been shown to be safe and effective at stimulating an immune response against other pathogens in multiple phase I and early phase II trials.
Powdered vaccine
Cambridge COVID vaccine is a freeze dried powder and is therefore heat stable.It does not need to be cold-stored.
Its transport and transport and storage is easy and very cheap.
Needle free injection in human body
The powder form Cambridge COVID vaccine will be delivered in human body with the help of a intradermal Needle-free Injection.
This needle less injection system has been named PharmaJet Tropis® .
This injection system will deliver the COVID 19 vaccine into the body in less than a 1/10th of a second by spring-powered jet injection.
Cambridge corona vaccine gets funding
£1.9million fund has been given by Innovate UK, the UK government's innovation agency.
It has provided the funding for a collaboration between Cambridge spin-out company DIOSynVax, the University of Cambridge and the University Hospital Southampton NHS Foundation Trust.
This finding will speed up the third phase trials in UK and other countries.It will bring the vaccine sooner in market. #cambridgevaccine #coronavaccine #covidvaccine #dnavectordeliverysystem #emergencymanager #innovateUK #phase3triavaccine.
Cambridge COVID vaccine is multipurpose DNA vector delivery system based and customised COVID vaccine.
It is developed on a foundation of libraries of computer-generated antigen structures encoded by synthetic genes that can train the human immune system to target key regions of the virus and to produce beneficial anti-viral responses.
This 'laser-specific' computer generated approach is able to help avoid the adverse hyper-inflammatory immune responses that can be triggered by recognition of the wrong parts on the coronavirus's surface.
Professor Jonathan Heeney, head of the Laboratory of Viral Zoonotics at the University of Cambridge, and founder of DIOSynVax, said: "Our approach involves 3D computer modelling of the SARS-CoV-2 virus's structure. It uses information on the virus itself as well as its relatives - SARS, MERS and other coronaviruses carried by animals that threaten to 'spill-over' to humans again to cause future human epidemics."
He further says " Ultimately we aim to make a vaccine that will not only protect from SARS-CoV-2, but also other related coronaviruses that may spill over from animals to humans."
DNA vector based delivery system
DIOSynVax's is based around DNA vector based delivery system.Otherviral vaccines are based on RNA or adenoviruses to deliver their antigens.
These synthetic gene inserts are very versatile and can also be placed within a number of different vaccine delivery systems that other companies are using. Once an antigen is identified, the key piece of genetic code that the virus uses to produce the essential parts of its structure is inserted into a DNA parcel known as a vector. The body's immune cells take up the vector.
This DNA vector has already been shown to be safe and effective at stimulating an immune response against other pathogens in multiple phase I and early phase II trials.
Powdered vaccine
Cambridge COVID vaccine is a freeze dried powder and is therefore heat stable.It does not need to be cold-stored.
Its transport and transport and storage is easy and very cheap.
Needle free injection in human body
The powder form Cambridge COVID vaccine will be delivered in human body with the help of a intradermal Needle-free Injection.
This needle less injection system has been named PharmaJet Tropis® .
This injection system will deliver the COVID 19 vaccine into the body in less than a 1/10th of a second by spring-powered jet injection.
Cambridge corona vaccine gets funding
£1.9million fund has been given by Innovate UK, the UK government's innovation agency.
It has provided the funding for a collaboration between Cambridge spin-out company DIOSynVax, the University of Cambridge and the University Hospital Southampton NHS Foundation Trust.
This finding will speed up the third phase trials in UK and other countries.It will bring the vaccine sooner in market. #cambridgevaccine #coronavaccine #covidvaccine #dnavectordeliverysystem #emergencymanager #innovateUK #phase3triavaccine.
